Recently analysts have released their new ratings on some health care stocks.
The first health care stock on this list is Allergan PLC (AGN, Financial).
Cowen Inc. (COWN, Financial) confirmed its outperform rating on shares of the Dublin-based global pharmaceutical company as reported by the StreetInsider.com website.
The U.S. diversified financial services firm lowered its price target on Allergan to $280 per share. This represents a 30% downside from the previous price target of $400 per share.
Before Cowen projected the new price level for Allergan to be reached by the health care stock on the New York Stock Exchange within the next 12 trading months, the Dublin-based global pharmaceutical company had an average target price of $250.72 per share.
This was a mean of 18 estimates of analysts who were surveyed. These estimates ranged between a low of $193 per share and a high of $400 per share.
Allergan is trading at $189.27 per share on the New York Stock Exchange with a market capitalization of $63.27 billion, a price-book (P/B) ratio of 0.90, a price-sales (P/S) ratio of 4.43 and a price-earnings (P/E) ratio of 6.51. The forward P/E ratio is 10.81.
For full fiscal year 2017 and 2018, analysts forecast an EPS of $16.21 and an EPS of $17.2.
Allergan distributes an annual dividend of $2.80 – through quarterly payments of 70 cents – to its shareholders for a dividend yield of 1.42%.
GuruFocus gives Allergan a financial strength rating of 4 out of 10. Concerning its profitability and growth prospects, GuruFocus assigns this health care stock a rating of 6 out of 10.
The second health care stock on this list is Abbott Laboratories (ABT, Financial).
Analysts have raised their price targets on shares of the U.S. multinational health care company, headquartered in Lake Bluff, Illinois, over the last two trading days.
As reported by the StreetInsider.com website, Jefferies LLC increased its price target on Abbott Labs by 12.1% to $65 per share. Jefferies' previous price target on Abbott Labs’ shares was $58 per unit. Jefferies keeps a buy rating on Abbott Labs.
Morgan Stanley (MS, Financial) has also increased its price target on Abbott Labs to $60 per share. This represents a 13.21% upside from the previous target price of $53 per share of the U.S. global health care stock. Morgan Stanley maintains an equal weight rating on Abbott Labs.
In addition, while keeping a buy rating on Abbott Labs, Stifel Financial Corp. (SF) increased by 8.6% its price target on shares of the U.S. global health care company to $63 per unit. The previous target price of Stifel Financial on shares of Abbott Labs was $58 per unit.
Waiting to be updated with the most recent estimates, Abbott Labs’ average target price is $60.78. This is a mean of 18 estimates that range between a low of $50 per share and a high of $68 per share.
The recommendation rating on Abbott Labs is currently 2 out of 5.
The health care stock is trading at $56 per share on the New York Stock Exchange with a market capitalization of $97.3 billion. The P/B ratio is 3.07, the P/S ratio is 3.83, the P/E ratio is 44.09, and the forward P/E ratio is 20.12.
For full fiscal years 2017 and 2018, analysts forecast an EPS of $2.5 and an EPS of $2.82.
The company distributes an annual dividend of $1.06 – through quarterly payments of 26.5 cents – to its shareholders for a dividend yield of 1.94%.
GuruFocus assigns Abbott Labs a financial strength rating of 5 out of 10 and a profitability and growth rating of 7 out of 10.
The third health care stock on this list is Shire PLC (SHPG, Financial).
According to thefly.com website, David Buck, analyst at FBR Capital, started to cover shares of Shire with a buy rating.
The U.S. investment banking and brokerage firm set a price target of $201 per share for Shire. This target price will drag Shire’s average target price down a little bit to $224.29 per share from the current value of $226.08 per share. The latter is a mean of 13 estimates of analysts who were surveyed. These estimates range between a low of $159 per share and a high of $325 per share.
Shire is trading at $147.82 per share on the Nasdaq stock exchange with a market capitalization of $44.93 billion. The P/B ratio is 1.37, the P/E ratio is 53.55, the P/S ratio is 2.93, and the forward P/E ratio is 8.91.
For fiscal years 2017 and 2018, analysts forecast an EPS of $14.92 and an EPS of $16.14.
Shire distributes an annual dividend of 92 cents to its shareholders for a dividend yield of 0.60%.
GuruFocus assigns Shire a financial strength rating of 4 out of 10 and a profitability and growth rating of 7 out of 10.
Buck also started to cover shares of Jazz Pharmaceuticals PLC (JAZZ, Financial) – the last health care stock on this list –Â with a buy rating, reports thefly.com.
FBR Capital set a price target of $206 per share of Jazz Pharmaceuticals. This target price will drag Jazz Pharmaceuticals’ average target price up to approximately $182.63 per share from the current value of $181.52 per share. The latter is a mean of 21 estimates of analysts who were surveyed. These estimates range between a low of $144 per share and a high of $210 per share.
The recommendation rating is currently set on a buy recommendation with a value of 2.1 out of a total of 5.
Jazz Pharmaceuticals is trading at $145 per share on the Nasdaq stock exchange with a market capitalization of $8.71 billion. The P/B ratio is 3.98, the P/E ratio is 22.12, the P/S ratio is 5.75, and the forward P/E ratio is 10.89.
For fiscal years 2017 and 2018, analysts forecast an EPS of $10.88 and an EPS of $12.98.
GuruFocus assigns Jazz Pharmaceuticals a financial strength rating of 5 out of 10 and a profitability and growth rating of 8 out of 10.
Disclosure: I have no position in any stock mentioned in this article.
